Inspire Medical Systems Stock (NYSE: INSP)

Inspire Medical Systems (NYSE:INSP) Stock, Quote.Headers.trade-ideas

Inspire Medical Systems

Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.

Analyst sees stock go up

Analyst Color

Equities

Large Cap

News

Upgrades

Health Care

Price Target

Analyst Ratings

Movers

Trading Ideas

General

INSP

BofA upgrades Inspire Medical to Buy, setting a $255 price target. The company aims for $950 million in 2025 revenue, with a focus on new product launches and expansion.

Inspire Medical&#39;s Strong 2025 Outlook And Upcoming Inspire V Launch Earns Analyst Upgrade

Intraday Update

Markets

ADMA

APLD

COMP

HLNE

IBRX

MERC

MSTR

PLTR

RLAY

SDST

SMMT

STKL

TERN

TSLA

Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday

Shopify

ANGI

AXON

AZPN

FTNT

ILMN

LUMN

PETQ

RYAM

SHOP

SNOW

SWIM

UPST

VCYT

Shopify Posts Upbeat Earnings, Joins Axon Enterprise, Aspen Technology, Illumina, Global Payments And Other Big Stocks Moving Higher On Wednesday

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems Inc

Inspecs Group PLC

Insperity Inc

Inspira Technologies Oxy B.H.N. Ltd. - Ordinary Shares

Inspira Technologies Oxy BHN Ltd

Inspira Technologies Oxy B.H.N. Ltd. - Warrant

Inspirato Inc

Inspirato Incorporated - Class A Common Stock

Inspire 100 ETF

Inspire Corporate Bond ETF

Inspire Global Hope ETF

Inspire International ETF

INSPIRE SEMICONDUCTOR HLD by INSPIRE SEMICONDUCTOR HLDGS INC.

Inspire Semiconductor Holdings Inc

Inspire Small/Mid Cap ETF

Inspire Tactical Balanced ETF

Inspire Veterinary Partners, Inc. - Class A Common Stock

Inspire Veterinary Partners Inc

InspireMD Inc

Inspired Entertainment, Inc. - Common Stock

Inspired Entertainment Inc

Rumors

AAPL

"Apple Is Rumored To Equip Its In-House Developed 5G Modem Chip Into The New iPhone SE 4 Set To Launch In Early 2025, Sources From The Upstream Supply Chain Believe The Chip Is Unlikely To Catch Up With Competitors In Terms Of Performance Until 2026" - DigiTimes Alert

XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) has outperformed Bitcoin and Ethereum over the past month, following <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42296482/xrp-price-explodes-415-in-30-days-experts-analyze-why-xrp-is-going-up">Ripple's favourable legal developments</a>. 
The cryptocurrency peaked at $2.82—its highest level in nearly seven years—triggering speculation of even larger gains.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.38</td>
<td>$136 billion</td>
<td>-7.15%</td>
<td>+1.5%</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$98,442.51</td>
<td>$1.94 trillion</td>
<td>-1.6%</td>
<td>+3.7%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$3,859.76</td>
<td>$465 billion</td>
<td>-3.2%</td>
<td>+7.4%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Prominent crypto trader Ali Martinez sees XRP as both &#8220;overbought and undervalued.&#8221; 
He <a href="https://x.com/ali_charts/status/1865720166514040862?s=46">highlights</a> its breakout from a multi-year symmetrical triangle, setting conservative and optimistic price targets of $8.40 and $48.12, respectively.
 In the short term, Martinez predicts a potential dip to $2.25, presenting a buy opportunity with a target of $4.40.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24XRP&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$XRP</a>: 3 consecutive bull pennants! We should all be praying for a retest of $2.25 to buy the dip and target $4.40! <a href="https://t.co/KgXnM929yk">pic.twitter.com/KgXnM929yk</a>
&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1866059088272007457?ref_src=twsrc%5Etfw">December 9, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Trader CrediBULL Crypto analyzes XRP's structure using the Elliott Wave theory, <a href="https://x.com/CredibleCrypto/status/1865868825964458202">suggesting</a> that XRP has completed its first wave from $1.27 and is now in a corrective phase. 
Depending on market conditions, this phase could resolve as an expanded flat or a more bullish running flat, which wouldn't dip below $2.17.
Community News: Ripple CEO Brad Garlinghouse voiced strong criticism of former SEC Chair Gary Gensler during an interview on 60 Minutes on Sunday. 
Garlinghouse attributed much of the crypto industry's <a href="https://www.benzinga.com/24/12/42382407/ripple-ceo-brad-garlinhouse-admits-204m-crypto-super-political-action-committee-wouldnt-exist-if-gary-gensler-hadnt-been-the-sec-chair">regulatory struggles to Gensler's leadership</a>, which he says led to Ripple and others forming the FairShake super PAC.
&#8220;FairShake wouldn't exist if the SEC had a different chairman,&#8221; Garlinghouse said, framing the PAC as a response to what he calls a &#8220;war on crypto.&#8221;
FairShake, funded by Ripple and two other companies, aims to promote fair policies for the crypto industry and push back against what it sees as overreach by regulators.
What's Next: XRP's rally comes amid broader altcoin strength and signals growing market optimism following Ripple's legal victories. 
The coin's ability to sustain gains and break higher will depend on whether it can hold key support levels during any dip.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/24/12/42348639/exclusive-investors-say-they-missed-out-on-xrp-opportunity-heres-what-percent-say-theyre-buying-on-pullbacks">EXCLUSIVE: What Percent Of Investors Who Missed XRP Are Buying The Dip?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$XRP

XRP Price Surges 328% In A Month, Outpaces Bitcoin, Ethereum: How High Can XRP Go?

Shelter Insurance&#xAE; (Shelter), a property and casualty (P&amp;C) insurance company offering insurance sold by agents in 21 states, and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.guidewire.com%2F&amp;esheet=54160514&amp;newsitemid=20241209192574&amp;lan=en-US&amp;anchor=Guidewire&amp;index=1&amp;md5=aee47b9442ccf200ca88ec9467cffbf7">Guidewire</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) announced that Shelter selected <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.guidewire.com%2Fproducts%2Finsurancesuite%2F&amp;esheet=54160514&amp;newsitemid=20241209192574&amp;lan=en-US&amp;anchor=Guidewire+InsuranceSuite&amp;index=2&amp;md5=3c6e598b3f410e1b3255d8361b901058">Guidewire InsuranceSuite</a> to power the company's core business, simplify its IT operations and help deliver additional value to agents, policyholders and employees. The selection and implementation of Guidewire is a key component of Shelter's Monarch business transformation. The Monarch transformation will focus on improving and expanding Shelter's capabilities to enable Shelter's continued success in the market. <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.guidewire.com%2Fpartnerconnect%2F&amp;esheet=54160514&amp;newsitemid=20241209192574&amp;lan=en-US&amp;anchor=Guidewire+PartnerConnect&amp;index=3&amp;md5=a766f8d3d93050bb114ac6c4385722b5">Guidewire PartnerConnect</a> Consulting Global Strategic member <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pwc.com%2Fus%2Fen%2F&amp;esheet=54160514&amp;newsitemid=20241209192574&amp;lan=en-US&amp;anchor=PwC&amp;index=4&amp;md5=be799a42bd4103ca92408479c145136e">PwC</a> has been selected to lead the implementation project.

GWRE

Shelter Insurance Selects Guidewire To Power The Co's Core Business, Simplify Its IT Operations And Help Deliver Additional Value To Agents, Policyholders And Employees

RBC Capital analyst Leonid Timashev reiterates Legend Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) with a Outperform and maintains $86 price target.

Reiteration

LEGN

RBC Capital Reiterates Outperform on Legend Biotech, Maintains $86 Price Target

Offerings

WOLF

Wolfspeed Files For Common Stock Offering Of Up To $200M

HUIZ

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

MicroStrategy Sells 5.42M Shares For $2.13B Under $21B Sales Agreement, Acquires 21,550 Bitcoins For $2.1B At $98,783 Each, Increasing Total Holdings To 423,650 BTC At $25.6B Total Cost; Reports BTC Yields Of 43.2% For Q4 And 68.7% YTD 2024

Macy's, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) today issued the below statement following the press release and presentation issued by Barington Capital Group, L.P. ("Barington") and Thor Equities LLC ("Thor"):
The Macy's, Inc. Board of Directors and management team are committed to delivering sustainable, profitable growth and driving shareholder value. We have consistently demonstrated open-mindedness, including with respect to regularly reviewing the Company's strategy and capital allocation framework and exploring all paths to enhance value.
We remain confident in our Bold New Chapter strategy, which continues to gain traction across all three of its pillars, and we expect to share further details regarding our progress when we report our full third quarter results and provide our fourth quarter and full year outlook.
We will continue to act in the best interests of the Company and all Macy's, Inc. shareholders and we look forward to engaging with our shareholders, including Barington and Thor, as we further advance our initiatives and execute toward our long-term goals.
Bank of America Securities and Wells Fargo are acting as financial advisors and Wachtell, Lipton, Rosen &amp; Katz is acting as legal advisor to the Company.

Management

Macy's Reiterates Commitment To Shareholder Value Creation Amid Barington Capital Presentation, Highlights Confidence In Bold New Chapter Strategy And Ongoing Engagement With Shareholders Ahead Of Q3 Results And Outlook Updates

RBC Capital analyst Elvira Scotto maintains Energy Transfer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>) with a Outperform and raises the price target from $20 to $23.

RBC Capital Maintains Outperform on Energy Transfer, Raises Price Target to $23

RBC Capital analyst Conor McNamara maintains Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) with a Outperform and raises the price target from $369 to $481.

RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $481

Biotech

SONN

Sonnet BioTherapeutics Announces Results Of SON-1010 At Highest Dose Have Been Formally Evaluated By Safety Review Committee In Phase 1 SB101 Trial; Max Tolerated Dose Was Set At 1200 ng/kg

Northeast Bank (the "Bank") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBN#NASDAQ">NBN</a>) announced today that it has entered into an equity distribution agreement with Piper Sandler &amp; Co. ("Piper Sandler") and Keefe, Bruyette &amp; Woods, Inc. ("KBW") for the offer and sale from time to time of shares of its voting common stock having an aggregate offering price of up to $75,000,000.00 (the "Shares") in an at-the-market offering. All of the Shares to be sold in the offering will be offered by the Bank.
The Bank intends to use the net proceeds from the offering for general corporate purposes, including the support of additional growth.
The Shares will be offered through Piper Sandler and KBW, as the distribution agents. Sales of the Shares, if any, will be made from time to time in negotiated transactions at market prices prevailing at the time of a sale or at negotiated prices, or as otherwise agreed with the distribution agents, and, as a result, sale prices may vary. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Northeast Bank Announces Commencement Of At-the-Market Offering Of $75M Voting Common Stock

Renewals Reached on WBD Linear Networks and HBO for Xfinity TV Customers as well as Expanded Streaming Rights for Max and Discovery+ in the U.S.
Sky and WBD Expand Their Partnership to Increase Content Available to Sky and NOW Customers Through a Bundle with the Max App, in Addition to Sky Cinema and the Existing Series on Sky Atlantic That Customers Will Enjoy Through Their Term

CMCSA

Comcast and Warner Bros. Discovery Announce Multi-Year Distribution Agreements That Will Deliver WBD's Portfolio Of Content To Xfinity And Sky UK And Ireland Customers Using Comcast's Global Technology Platform Across Linear Television, Apps, And Streaming Services

- Median Overall Survival (mOS) Not Yet Reached, Now Exceeds 7.7. Months at Latest Follow-Up in the 30 mg BIW Cohort in Patients Relapsed or Refractory to Venetoclax-Based Regimens -
- Overall Response Rate (ORR) of 56% Achieved to Date in Patient with Acute Myeloid Leukemia with Myelodysplasia Related Changes (AML MRC) Prospectively Enrolled in Two Expansion Cohorts; Exceeding Prespecified Target Response Rate of 33% - &nbsp;
NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLS#NASDAQ">SLS</a>) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced additional data from the expansion cohorts in the Phase 2 trial of SLS009, a highly selective CDK9 inhibitor, in relapsed/refractory acute myeloid leukemia (r/r AML).

SELLAS Announces Median Overall Survival Not Yet Reached, Now Exceeds 7.7. Months At Latest Follow-Up In The 30 mg BIW Cohort In Patients Relapsed Or Refractory To Venetoclax-Based Regimens;  Overall Response Rate Of 56% Achieved To Date In Patient With Acute Myeloid Leukemia With Myelodysplasia Related Changes Prospectively Enrolled In Two Expansion Cohorts; Exceeding Prespecified Target Response Rate Of 33%

Oracle Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) is finding itself at a pivotal crossroads as it juggles ambitious plans <a href="https://www.benzinga.com/topic/artificial-intelligence">in generative AI</a> (GenAI) and cloud infrastructure with the realities of cautious IT budgets. 
According to insights from JPMorgan analyst Mark R. Murphy, the tech giant's journey ahead is filled with both promise and challenges. With Oracle&#8217;s stock trading at around $195, Murphy's price target of $140 by December 2025 suggests a more tempered outlook.
<h2 class="wp-block-heading">GenAI: The Shiny Object Eating Into Budgets</h2>
Murphy highlights how the GenAI gold rush isn't all glitz and glamour. While Oracle&#8217;s partners see it as a catalyst for long-term software investments, the immediate impact is mixed. GenAI projects are shifting from ambitious &#8220;build-your-own&#8221; experiments to more practical &#8220;off-the-shelf&#8221; solutions, particularly for small to mid-sized businesses. Yet, he notes that this shift is cannibalizing other IT budgets, squeezing spending across the board.
For Oracle, this dynamic presents both an opportunity and a headache. As Murphy points out, Oracle's database partnerships (ODB@) position it as a vital player for global IT spenders reliant on legacy systems. However, the lingering complexity of customer demands and pricing pressures underscores the limits of even a marquee name in this competitive space.
Read Also: <a href="https://www.benzinga.com//node/42364367">How To Earn $500 A Month From Oracle Stock Ahead Of Q2 Earnings</a>
<h2 class="wp-block-heading">Cloud Wars: Oracle's Fourth-Mover Advantage</h2>
Oracle Cloud Infrastructure (OCI) continues to grow, but Murphy acknowledges that becoming the "fourth hyperscaler" remains an uphill battle. According to the GSI partner he consulted, OCI isn't vying to replace AWS, Azure, or Google Cloud. Instead, Oracle is betting on coexistence, offering solutions that allow customers to port legacy data systems into modern cloud environments.
Murphy views this strategy as both a strength and a limitation—keeping Oracle relevant but underscoring OCI's struggle to capture a dominant position. Meanwhile, hefty capital expenditures to scale OCI are putting pressure on free cash flow, a concern he highlights as testing investor patience.
<h2 class="wp-block-heading">2025: A Better Budgeting Horizon?</h2>
Looking ahead, Murphy remains cautiously optimistic about 2025, which he suggests could bring brighter days. Oracle's partner indicates that loosened purse strings might support both GenAI investments and the core IT spending required to sustain them. 
Until then, however, Oracle must navigate a "flat-to-slightly-improving" demand environment where cost-conscious customers dictate terms, the analyst notes.
<h2 class="wp-block-heading">The Verdict</h2>
JPMorgan&#8217;s Neutral stance and $140 price target reflect skepticism about Oracle's near-term upside. While the company's ambitions in GenAI and cloud make it a compelling story, the realities of pricing pressures and a complex demand landscape cannot be ignored. 
With OCI growth showing potential but high CapEx weighing on valuation, Murphy believes Oracle's tightrope walk between innovation and investor expectations will define its journey.
For now, Oracle remains a stock to watch—but perhaps not one to chase.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com//node/42383396">S&amp;P 500, Nasdaq Hit Record Close As November Jobs Data Beats Expectations: Fear &amp; Greed Index In &#8216;Neutral&#8217; Zone</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Tech

ORCL

Oracle Juggles GenAI Ambitions, Tight IT Budgets: What's Next For The Stock?

HeartCore Enterprises, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/HTCR#NASDAQ">HTCR</a>) ("HeartCore" or "the Company"), a leading enterprise software and data consulting services company based in Tokyo, announced a series of strategic initiatives designed to elevate the customer experience, enhance the value offered to current HeartCore CMS clients, and promote cross-selling opportunities.
Building on its recent <a href="https://www.globenewswire.com/Tracker?data=KhaMfRPpiLmLOoUFFufuDbwaAWd43v9YNdfTqLttIKCrvjybXOh3_OohXiQhs73exFzlnuCAA3csSMtbFfBkIP8ZUZ_vGeSOdioDbLAt9WeOta9_O1wYBuW8hZgpAJ10ZutY0oMcFZ_dRF8a6tpi-fTG8NsQ8vFdUY428piLaXu55jLm-1q3Xel0WhQy3G047-TqNfNlZpQlG8lOAjyGVY2Gwcn1chMjRMCzlY9AUXzwgvBI7mWKV_sUCY-XIS_L">expansion</a> of its CMS platform offering into a Software-as-a-Service model and strategic <a href="https://www.globenewswire.com/Tracker?data=dtKZGtYjgb7cCxK8BNx6NCNJTbk62fQzNaPc1dB2QIRiHOVtkrp-VetbXYRZ5zHIBznuCVYmsGNMw2h0yg3UbOknEvlV8OVFz1RVP0K2-rJQniD0b0zpxDWQamKi6ufBBWar42rZmiU4ajzHIjPmamah0P8uFYeE1lqWiueAuB51171fv70F4FNZ7It6DgMhK_uVT7AXtQ6Kd3s__ozxpnzI_Ao8RbvwT9f0Mt1ZGgX42UhcbULU8Qt0T5PYy-aLvvO5OtgpevVAQt9OUohxqg==">shift</a> to multi-year software licensing agreements, HeartCore will further invest in customer success by forming a dedicated team of sales and technical members to engage existing customers to maximize the use of CMS functionalities and provide customized support for their digital transformation efforts. Starting from October 2024, HeartCore activated ‘Health Check,' a process of conducting on-site customer visits to offer consultations and garner comprehensive feedback. These efforts have provided valuable insights into CMS usage, facilitated system upgrades and overhaul strategies, and optimized solutions tailored to individual client needs.
Additionally, the Company plans to explore cross-selling opportunities by actively recommending its WAF security product, which forms the foundation of Health Check. This strategy also emphasizes identifying prospects for website design projects and consulting engagements, with the ultimate goal of securing full-scale renewal projects, including site redesigns and improvements. 25.9% of the Company's direct and partner clients have utilized HeartCore's software services for over a decade. By continuing to invest in customer experience, proactively engaging clients, conducting Health Checks and leveraging cross-selling opportunities through this initiative, the Company projects 12% sales growth in FY 2025 from existing CMS customers.

HTCR

HeartCore Announces A Series Of Strategic Initiatives Designed To Elevate The Customer Experience, Enhance The Value Offered To Current HeartCore CMS Clients, And Promote Cross-Selling Opportunities

Market-Moving Exclusives

Exclusives

CRKN

EXCLUSIVE: Crown Electrokinetics Tells Benzinga 'Expected To Produce Up To An Estimated $40M In Reoccurring Annual Revenue'

EXCLUSIVE: Crown Electrokinetics Tells Benzinga Co. Announces Plans To Build Co-Own Reverse Osmosis Plant In Mexico To Desalinate Water Collected From Slant Wells

On Monday, Crown Electrokinetics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRKN#NASDAQ">CRKN</a>) announced that its Water Solutions division plans to construct and co-own a reverse osmosis (RO) water treatment plant in Cabo San Lucas, Mexico, to desalinate water collected from its proprietary design slant wells.
The company and 529 Capital, a real estate development firm in the Baja Peninsula, will co-build and co-own the new RO plant. Together, they will provide the region with a new, reliable supply of clean, safe drinking water.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42366347/taiwan-semi-set-to-power-taiwan-semiconductor-index-surge-in-2025-fueled-by-ai-demand" rel="noreferrer noopener">Chipmaker Taiwan Semiconductor Should See Business Grow 20% Fueled By AI Demand: Analyst</a>
The company said the initiative has the potential to generate up to $40 million in recurring annual revenue for Crown Electrokinetics.
The Baja Peninsula heavily relies on groundwater aquifers as a water source, many of which need to be more exploited. This creates severe challenges in securing a consistent, clean water supply in a region well known for its growing population and tourism industry.
Crown is providing an innovative solution to this critical problem by tapping into an unlimited rechargeable water source with its proprietary design slant wells.
The seawater collected by the slant wells must then undergo purification, which takes place in an RO plant. Advanced membrane filtration technology is used to desalinate, removing up to 99% of dissolved salts and contaminants.
The proposed RO plant should enable Crown and 529 Capital to provide clean drinking water to a select few resorts in Cabo San Lucas through a five-year cooperative partnership.
The cooperative partners will be able to have a reliable water supply, ensuring a sustainable and efficient solution.
In addition, Crown and the cooperative plan to impact the broader community by looking for opportunities to donate up to 500,000 gallons of clean drinking water per day to nearby needy areas, fostering a positive and lasting contribution to the region.
Crown's Water Solution division, spearheaded by Corey Boaz, President of Construction, plans to commence an environmental impact study immediately. At the same time, 529 Capital will start gathering the necessary permits in Mexico. Construction will likely begin in the summer of 2025, with an anticipated operational date in 2026.
Price Action: CRKN stock is up 11.10% at $0.277 premarket at last check Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42363171/uber-and-weride-come-together-to-launch-robotaxi-service-in-abu-dhabi" target="_blank" rel="noreferrer noopener">Uber And WeRide Partner For Robotaxi Service In Abu Dhabi</a></li>
</ul>

EXCLUSIVE: Crown And 529 Capital To Co-Build and Co-Own Reverse Osmosis Plant in Mexico

Safety Shot, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOT#NASDAQ">SHOT</a>) ("Safety Shot" or "the Company") today announced that its innovative alcohol-reducing dietary supplement, Sure Shot, is now available for purchase on the online store of a leading e-commerce platform. This platform is owned and operated by one of the largest big-box stores in the US, boasting a massive online presence and extensive distribution network. This expansion into the digital marketplace marks a significant step in Safety Shot's growth strategy, broadening its reach and providing consumers with greater accessibility to its products.

SHOT

Safety Shot Announces Sure Shot, Is Now Available For Purchase On The Online Store Of A Leading E-Commerce Platform

BofA upgraded Inspire Medical (INSP) to Buy from Neutral with a $255 price target Published first on TheFly – the ultimate source for real-time, ma...

Inspire Medical upgraded to Buy from Neutral at BofA

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Target downgraded, Chewy upgraded: Wall Street's top analyst calls

Inspire Medical upped to buy by BoA, improved margins cited

Franklin Small Cap Growth Fund Q3 2024 Commentary

Franklin Small Cap Growth SMA Fund Q3 2024 Commentary

Inspire Medical Systems: Getting Cheaper But Not There Yet

Invesco Main Street Small Cap Fund Q3 2024 Commentary

Leerink Partners analyst Mike Kratky maintained a Hold rating on Inspire Medical Systems (INSP – Research Report) on November 25 and set a price ta...

Leerink Partners Sticks to Their Hold Rating for Inspire Medical Systems (INSP)

Janus Henderson Global Life Sciences Diversified ADR Managed Account Q3 2024 Commentary

Comments

Inspire Medical Systems

Inspire Medical Systems (INSP) Forecast

Inspire Medical Systems (NYSE:INSP) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga